|会社名||Co-Diagnostics Inc （コ・ダイアグノスティックス）|
|分野（sector）||Health Care ヘルスケア|
|業種||バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care）|
|概要||事業概要 Co-Diagnostics Inc. is a molecular diagnostics company. The Company is engaged in developing manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules such as deoxyribonucleic acid and ribonucleic acid. It also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The Company uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis a drug resistant tuberculosis test hepatitis B and C Malaria dengue human immunodeficiency virus and Zika virus all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. コ・ダイアグノスティックスは米国の医療関連企業。主に、医療診断における試薬の開発・製造・販売に従事する。核酸分子の検出および分析の診断テストに使用される試薬を開発、完結型ラボ・システムを販売する。また、病気や遺伝的疾患の治療のため、DNAベ―スの試験プラットフォ―ムを開発する。本社所在地はユタ州ソルト・レ―ク・シティ―。 Co-Diagnostics, Inc. engages in the development, manufacture, and marketing of diagnostics technology. It offers design services, vector control, equipment, diagnostic, and research solutions. The company was founded by Brent C. Satterfield and Dwight H. Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.|
|本社所在地||2401 S. Foothill Drive Suite D Salt Lake City UT 84109 USA|
|代表者氏名||Dwight H. Egan ドワイト・エガン|
|代表者役職名||Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO）|
|市場名||NASDAQ Small Cap|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 Co-Diagnostics Inc revenues increased from $2K to $19K. Net loss increased 72% to $2.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 46% to $655K (expense) Sales and marketing increase of 26% to $239K (expense).|
Can CoDiagnostics, Inc. (CODX) Run Higher on Rising Earnings Estimates? 2020/05/21 16:20:04 Zacks Investment Research
CoDiagnostics, Inc. (CODX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
CoDiagnostics, Inc. (CODX) Moves to Strong Buy: Rationale Behind the Upgrade 2020/05/21 16:00:14 Zacks Investment Research
CoDiagnostics, Inc. (CODX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is CoDiagnostics (CODX) Outperforming Other Medical Stocks This Year? 2020/05/21 15:30:14 Zacks Investment Research
Is (CODX) Outperforming Other Medical Stocks This Year?
Top Analyst Upgrades and Downgrades: AbbVie, AEP, AB InBev, Arconic, Baidu, Best Buy, Co-Diagnostics, Cree, Exelon, Home Depot, NRG, T-Mobile, Walmart and More 2020/05/20 13:09:23 24/7 Wall street
Top Analyst Upgrades and Downgrades: Apple, Best Buy, Cinemark, Co-Diagnostics, DraftKings, Energizer, Novavax, Nvidia, Palo Alto, Petrobras and More 2020/05/18 13:06:41 24/7 Wall street
Co-Diagnostics stock rises as coronavirus escalates 2020/03/11 15:07:15 Yahoo Finance
Co-Diagnostics stocks rose as investors believe the company will be able to release a vaccine for the coronavirus. Yahoo Finance’s Alexis Christoforous joins the On The Move panel to discuss how the health companies are responding to the coronavirus.
The Zacks Analyst Blog Highlights: Buckle, Chipotle Mexican Grill, Co-Diagnostics, Moderna and Regeneron Pharmaceuticals 2020/03/11 13:09:00 Zacks Investment Research
The Zacks Analyst Blog Highlights: Buckle, Chipotle Mexican Grill, Co-Diagnostics, Moderna and Regeneron Pharmaceuticals
Co-Diagnostics down 39% on proliferation of COVID-19 competitors 2020/03/10 18:10:02 Seeking Alpha
Co-Diagnostics (CODX -38.9%) represents a shining example of the risks in playing a highly volatile stock amid market turmoil related to COVID-19. Shares a
Co-Diagnostics Sees Strong Demand for Its Coronavirus Kits 2020/03/05 17:00:45 The Street
Co-Diagnostics reports strong global demand for its coronavirus detection kits.
Co-Diagnostics Says COVID-19 Test Kit Demand Surges In Recent Weeks 2020/03/05 13:40:09 Benzinga
Co-Diagnostics Inc (NASDAQ: CODX ) shares have been on a roll following the outbreak the COVID-19 , the latest coronavirus strain that has stirred fears and anxiety. Shares received another boost Thursday following disclosure from the company that its COVID-19 test kit demand remains robust. The molecular diagnostics company that uses a patented platform for the development of diagnostic tests said demand, both domestic and international, surged for its COVID-19 detection kits in recent weeks, leading to increased product shipments. The increase comes after the FDA changed its policy Feb. 20 and the … Full story available on Benzinga.com
Co-Diagnostics Inc to Discuss New Coronavirus Test During GenomeWeb Webinar on Feb 5 2020/02/04 11:30:00 Business Wire
SALT LAKE CITY,--(BUSINESS WIRE)---- $CODX #GenomeWeb--Co-Diagnostics Inc to discuss new coronavirus test during GenomeWebinar on Feb 5, as well as multiplex applications for vector control solutions
Co-Diagnostics Inc CEO Discusses Novel Coronavirus with CNBC Squawk Box Asia 2020/01/28 11:30:00 Business Wire
SALT LAKE CITY--(BUSINESS WIRE)---- $CODX #Biotech--Co-Diagnostics CEO discusses novel coronavirus with CNBC Squawk Box Asia, including importance of accurate diagnostics and test announced last week
Co-Diagnostics launches $5M direct offering; shares down 16% premarket 2020/01/24 13:33:41 Seeking Alpha
Co-Diagnostics (NASDAQ:CODX) has entered into definitive agreements with institutional investors for the purchase of 3,448,278 common shares at $1.45 per s
Co-Diagnostics Announces $5.0 Million Registered Direct Offering Priced At-the-Market 2020/01/24 13:00:00 Business Wire
SALT LAKE CITY--(BUSINESS WIRE)---- $CODX #CODX--Co-Diagnostics announces $5.0 Million registered direct offering, following news about beginning work on a test for the new coronavirus.
Co-Diagnostics Rallies On Plans To Develop Screening Test For Coronavirus 2020/01/23 13:37:53 Benzinga
Shares of molecular diagnostic company Co-Diagnostics Inc (NASDAQ: CODX ) are riding high on the Wuhan coronavirus wave, at their highest level in about a year. The Utah-based company said it has completed principle design work for a PCR screening test for the new coronavirus, 2019-nCoV, which will potentially detect the virus. Co-Diagnostics said the new test uses its patented CoPrimer technology and was designed to use its proprietary software system. The test would follow the guidelines published by the World Health Organization and Centers for Disease Control, the company added. See Also: The Daily Biotech Pulse: … Full story available on Benzinga.com
関連キーワード （バイオテクノロジ―_メディカルリサ―チ 米国株 コ・ダイアグノスティックス CODX Co-Diagnostics Inc.）